Browsing by Subject "177Lu-lilotomab satetraxetan"

Now showing items 1-1 of 1

Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients

Stokke, Caroline; Blakkisrud, Johan; Løndalen, Ayca; Dahle, Jostein; Martinsen, Anne Catrine Trægde; Holte, Harald; Kolstad, Arne (Springer Verlag, 2018-02-22)

Purpose: 177Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been ...